Literature DB >> 14568419

Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes.

Moganavelli Singh1, Mario Ariatti.   

Abstract

Unilamellar activated cationic liposomes containing 3beta[N-(N',N'-dimethylaminopropane)-carbamoyl] cholesterol, dioleoyl phosphatidylethanolamine (DOPE) and the N-hydroxysuccinimide ester of cholesteryl hemisuccinate (4:5:1, molar ratio) have been prepared and their DNA-binding capacity has been assessed in a gel retardation assay. Ternary complexes composed of activated cationic liposomes, carbodiimide-cationized asialoorosomucoid (Me+AOM) and pRSVL plasmid DNA were assembled for receptor-mediated DNA delivery into cells expressing the asialoglycoprotein receptor (ASGP-R). Binding of complexes in which Me+AOM was replaced by fluoresceinated Me+AOM (FMe+AOM) to the human hepatocellular cell line HepG2 at 4 degrees C was severely reduced by co-incubation with asialoorosomucoid (AOM). Moreover, assemblies containing liposomes, pRSVL DNA and Me+AOM (8:1:4, w/w/w) promoted high levels of luciferase activity in this cell line (1.3 x 10(7) relative light units/mg soluble cell protein). Assays conducted in the presence of a hundred-fold excess of the ligand AOM afforded considerably lower levels of transfection (2.5 x 10(5) relative light units/mg soluble cell protein). In contrast, the highest level of luciferase activity achieved with liposome, pRSVL DNA, AOM complexes was only a quarter of the best levels obtained with liposome, pRSVL DNA, Me+AOM assemblies. These findings strongly support the notion that complexes gain entry into hepatocyte-derived cells by ASGP-R mediation and that they are potentially useful gene carriers to liver hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568419     DOI: 10.1016/s0168-3659(03)00360-2

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  8 in total

1.  Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine.

Authors:  Ulrika Westerlind; Jacob Westman; Elisabeth Törnquist; C I Edvard Smith; Stefan Oscarson; Martina Lahmann; Thomas Norberg
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

2.  Feasibility on systemic delivery of asialoorosomucoid complex to hepatic origin cells mediated by asialoglycoprotein receptor.

Authors:  Sun Jun; Jinsong Xia; Yu Wang; Yuzhe Wang; Zong Yiqiang; Qu Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 3.  A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.

Authors:  Samaresh Sau; Katyayani Tatiparti; Hashem O Alsaab; Sushil K Kashaw; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-03-15       Impact factor: 7.851

4.  Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro.

Authors:  Dhireshan Singh; Moganavelli Singh
Journal:  Pharmaceutics       Date:  2021-02-24       Impact factor: 6.321

5.  Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy.

Authors:  Aishwarya Saraswat; Hari Priya Vemana; Vikas V Dukhande; Ketan Patel
Journal:  Heliyon       Date:  2022-01-03

6.  Poly-L-Lysine-Lactobionic Acid-Capped Selenium Nanoparticles for Liver-Targeted Gene Delivery.

Authors:  Shaigan Naidoo; Aliscia Daniels; Saffiya Habib; Moganavelli Singh
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

Review 7.  Efficient hepatic delivery of drugs: novel strategies and their significance.

Authors:  Nidhi Mishra; Narayan Prasad Yadav; Vineet Kumar Rai; Priyam Sinha; Kuldeep Singh Yadav; Sanyog Jain; Sumit Arora
Journal:  Biomed Res Int       Date:  2013-10-28       Impact factor: 3.411

8.  Diacetylenic lipids in the design of stable lipopolymers able to complex and protect plasmid DNA.

Authors:  C Facundo Temprana; M Jimena Prieto; Daniela E Igartúa; A Lis Femia; M Silvia Amor; Silvia Del Valle Alonso
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.